Streetbeat News

Equity Actions

THRY

Thryv Holdings shares declined following the release of preliminary Q3 results. The company also announced a $75 million public offering and a proposed acquisition of Keap.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:12 pm

EA

HERO

NERD

Electronic Arts (EA) reported Q2 earnings with EPS beating estimates, but revenue slightly missing expectations. Net bookings hit a record, and American Football is on track for $1 billion in net bookings for FY25. EA raised its full-year EPS and revenue guidance. The company also repurchased shares and declared a dividend. EA shares rose premarket.

Portfolio Pulse from Lekha Gupta

October 30, 2024 | 12:02 pm

APDN

Applied DNA Sciences announced the pricing of a registered direct offering of 20,312,500 shares at $0.32 per share, along with a concurrent private placement. This news has led to a decline in the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:21 am

APDN

Applied DNA Sciences has announced a registered direct offering of 20,312,500 shares at a price of $0.32 per share.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:19 am

NBIX

Neurocrine Biosciences shares rose following strong Q3 results, an increased annual revenue outlook for valbenazine, and a $300 million stock buyback authorization.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:15 am

OIS

Oil States International's board has approved a new $50 million common stock repurchase program, set to expire in October 2026.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:06 am

NBIX

Neurocrine Biosciences has announced a $300 million stock buyback plan, with an accelerated share repurchase transaction to follow, subject to market conditions.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:06 am

SJW

SJW Group has filed a prospectus for the potential offer and sale of up to $200 million in common stock. This move could impact the company's stock price and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:11 am

VERA

Vera Therapeutics has announced a $300 million public offering, pricing 7,142,858 Class A common shares at $42 per share.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:03 am

PRCT

PROCEPT BioRobotics has announced the pricing of a $175 million public offering, selling 1,923,076 common shares at $91 per share.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 7:55 am